Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 21, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 1,350,000 ordinary shares.
- Purchase Price: 1,278.28 pence per share.
- Treasury Shares Held: 369,287,158 shares (representing 6.53% of total voting rights).
- Shares in Issue: 5,652,945,660 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the August 21 transaction. The total number of shares held in Treasury now represents 6.53% of the total voting rights in the Company. The number of shares in issue remains 5,652,945,660, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made solely to comply with disclosure rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,652,945,660) for accurate calculation of ownership percentages under disclosure rules.
- Confirm the updated Treasury share count (369,287,158) and its impact on the total voting rights structure (6.53%).
- Note that this filing is a regulatory disclosure of a share buyback and does not contain financial performance data for the period.